Q1 Earnings Estimate for COCP Issued By Noble Financial

Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Stock analysts at Noble Financial issued their Q1 2027 EPS estimates for shares of Cocrystal Pharma in a report issued on Tuesday, November 17th. Noble Financial analyst R. Leboyer expects that the company will post earnings of ($0.17) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.76) per share. Noble Financial also issued estimates for Cocrystal Pharma’s Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.17) EPS and Q4 2027 earnings at ($0.20) EPS.

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.

Several other research firms have also issued reports on COCP. HC Wainwright restated a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

Get Our Latest Report on COCP

Cocrystal Pharma Stock Down 0.7%

Shares of NASDAQ:COCP opened at $0.97 on Wednesday. The stock has a market cap of $18.68 million, a PE ratio of -1.26 and a beta of 1.60. The company’s fifty day moving average is $1.06 and its 200 day moving average is $1.10. Cocrystal Pharma has a 52 week low of $0.76 and a 52 week high of $2.03.

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.

Recommended Stories

Earnings History and Estimates for Cocrystal Pharma (NASDAQ:COCP)

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.